Neuroimaging Biomarkers for Predicting rTMS Response in OCD
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 15 Jan 2021
- Planned end
- 15 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Active bilateral DMPFC
- Active right-sided OFC
- Record updated
- 18 April 2023
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (20)Hide the full registry criteria
Who can take part
- meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for OCD with a moderate level of severity as defined by a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 18
- stable on Serotonin Re-uptake Inhibitor (SRI) medication for at least 8 weeks prior to (with plans to continue throughout) the study Note: Medications that are known to increase cortical excitability (e.g., buprorion, maprotiline, tricyclic antidepressants, classical antipsychotics) or to have an inhibitory effect on brain excitability (e.g., anti-convulsants, benzodiazepines, and atypical antipsychotics), or any other medications with relative hazard for use in TMS will be allowed upon review of medications and/or motor threshold determination by TMS specialist
- failed at least 1 prior trial of standard first-line OCD treatment per American Psychological Association (APA) Practice Guidelines (serotonin reuptake inhibitor [SRI] or cognitive behavioral therapy with exposure and response prevention)OR had refused these treatments for individual reasons
- capacity to provide informed consent
- ability to tolerate clinical study procedures
- successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI) without any contraindications
Who cannot take part
- Planning to commence Cognitive Behavioral Therapy (that includes exposure and response prevention) during the period of the study or have begun Cognitive Behavioral Therapy within 8 weeks prior to enrollment (assessed during baseline by study MD)
- Positive urine screen for illicit drugs (assessed via urine dipstick if screening appointment was more than 30 days ago) [Exceptions: (1) any prescribed medication that participant is currently taking and (2) positive cocaine metabolite after consumption of coca tea]
- History of receiving Electroconvulsive Therapy (ECT) (assessed during baseline by study MD)
- Current bipolar disorder (assessed during baseline if screening appointment was more than 30 days ago - SCID-5 Module D)
- Current moderate or severe Alcohol Usage Disorder or Substance Usage Disorder (except nicotine and caffeine) according to the DSM-5 criteria (assessed only if screening appointment was more than 12 months ago - SCID-5 Module E)
- Current eating disorder (assessed during baseline if screening appointment was more than 3 months ago - SCID-5 Module I)
- History of seizure, having an EEG, stroke, head injury (including neurosurgery), implanted devices, frequent or severe headaches, brain related conditions (e.g., intracranial mass lesions globe injuries, hydrocephalus), illness that caused brain injury or first degree relative with seizure disorder (assessed during screening via medical history assessment and TMS Safety Screen by study MD)
- Individuals with primary hoarding disorder without a DSM-5 OCD diagnosis (as determined by SCID-5 and YBOCS checklist assessed only if screening appointment was more than 30 days ago)
- History of any implanted device or psychosurgery (assessed during baseline by study MD)
- Age of OCD symptom onset >30
- Current psychosis (re-assessed only if screening appointment was more than 30 days ago - Structured Clinical Interview for DSM-IV (SCID) - 5 Module B)
- Severe depression [Note: 17-item Hamilton Depression Rating Scale (HDRS-17) must be less or equal to 20 to enter study, assessed during baseline if last assessment was more than 1 week ago]
- Current active suicidality (as determined by C-SSRS at baseline of 3 or above)
- Pregnant or nursing females (assessed via urine dipstick if screening appointment was more than 30 days ago)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Obsessive-compulsive disorder
This trial is currently available in United States.
- Department of Psychiatry and Behavioral Sciences, Stanford School of MedicineStanford, United StatesContact: Nick Bassano, MSWTaking people
About the trial
What the trial wants to find out
This study evaluates an accelerated schedule of theta-burst stimulation using a Transcranial Magnetic Stimulation (TMS) device for treatment-resistant Obsessive Compulsive Disorder (OCD). In a randomized fashion, half the participants will receive accelerated theta-burst stimulation at the dorsomedial prefrontal cortex (DMPFC), while half will receive accelerated theta-burst stimulation at the right orbitofrontal (rOFC) site.
The 2 groups in the trial
- bilateral DMPFCExisting treatment, for comparison
This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.
Treatment: Active bilateral DMPFC
- right OFCExisting treatment, for comparison
This arm will receive continuous theta-burst stimulation to the right OFC site.
Treatment: Active right-sided OFC
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Individualized Neuroimaging Biomarkers for Predicting rTMS Response in OCD
- Criteria questions
- Built from NCT04286126, who can take part
- Record updated
- 18 April 2023